Back to search

Aristotle University Of Thessaloniki (AUTH)

Μελέτη της οδού μεταγωγής σήματος του επιδερμικού αυξητικού παράγοντα σε ασθενείς με βασικού τύπου καρκίνου του μαστού

Abstract

dc:description

The aim of this study was to investigate the overall survival (Overall Survival) and Disease Free Survival (Disease Free Survival) of patients receiving intensive sequential adjuvant chemotherapy. Furthermore we evaluate the expression of EGFR/PI3K/AKT/mTOR pathway in combination with PTEN in the subgroup of patients with triple negative (ΤΝ) immunophenotype. One hundred thirty one patients with operable high risk breast cancer, received additional intensive sequential chemotherapy with or without paclitaxel from a randomized study were not investigated. Among these patients, EGFR was successfully evaluated in 129 patients, p-mTOR on 127, PTEN in 120, the p-Akt308 in 119, and p-Akt473 in 119 tumors. The HER2 gene status has also been evaluated with FISH. The immunohistochemical subtypes were further identified based on HER2 protein expression and Ki67 (eg, Luminal B tumors were classified as HER2 and/or Ki67 positive). The mRNA expression of ESR1, PgR and HER2 genes were also assessed by qRT-PCR. Of the tumors examined, 26% were Luminal A, 40.5% Luminal B, 12% Luminal-HER2, 8% HER2-positive, 13% TN and 9% BT. The percentage of patients who were disease free for 5 years for each group was: 81.4% for Luminal A, 75.8% for Luminal B, 65.3% for Luminal-HER2, 68.6% for HER2-positive, 62.1% for TN, and 62.9% for the BT group. Regarding the 5-year survival for these groups it was 89.9%, 88.7%, 84.2%, 84.8%, 73% and 73.7%, respectively. The molecular subtypes Luminal A and Luminal B had a statistically better DFS than other molecular subgroups, followed by the HER2-positive, Luminal-HER2 and TN. Patients with TN phenotype had worse OS compared with all other subtypes. The mean duration of follow up was 104.8 months. Furthermore, the present study investigated the pathway PI3K/AKT/ mTOR in ΤΝ breast cancers from paraffin blocks, collected on behalf of the studies HE 10/97 and HE 10/00. We illustrated that the pathway is activated in the majority of ΤΝ tumors of our study. The expression of markers EGFR, p-Akt308, p-Akt474 (nuclear and cytoplasmic and combined) and p-mTOR differed significantly between the TN tumours with high Ki67 and those with low Ki67. Our observation suggests that there are different subtypes among the ΤΝ breast cancers. It is noted that after multivariate analysis, the stated three subtypes had on increased risk of recurrence and death compared with the subtype tumours Luminal A tumors. Patients treated with paclitaxel did not obtain any benefit, even when the four subtypes were analysed separately. In conclusion, our study is the first that examined the EGFR/PI3K/AKT/ mTOR pathway in combination with PTEN in patients with triple negative breast cancer who received intensive, sequential, adjuvant chemotherapy. We showed that the pathway is activated in the vast majority of ΤΝ breast cancers. Furthermore we showed that expression of EGFR, p-mTOR, p-Akt308 and p-Akt473 differed significantly between the ΤΝ tumours with high and low Ki67. None of the above biomarkers had prognostic or predictive value.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2012

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Skarlos, Pantelis
  • Σκάρλος, Παντελής

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/28353

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Skarlos, Pantelis; Σκάρλος, Παντελής. Μελέτη της οδού μεταγωγής σήματος του επιδερμικού αυξητικού παράγοντα σε ασθενείς με βασικού τύπου καρκίνου του μαστού. Aristotle University Of Thessaloniki (AUTH), 2012. http://hdl.handle.net/10442/hedi/28353